Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
--
EV/EBITDA
-0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
46,288,600
CFO
$-226.60 Mln
EBITDA
$-221.49 Mln
Net Profit
$-291.51 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aadi Bioscience (AADI)
| -50.2 | -20.7 | -49.8 | -12.3 | -54.4 | -29.5 | -- |
|
BSE Sensex*
| 3.9 | 3.5 | 7.0 | 9.8 | 15.5 | 21.9 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Aadi Bioscience (AADI)
| 55.6 | -84.3 | -46.9 | 64.3 | 57.2 | -63.3 | -64.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of... sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California. Read more
Founder, Secretary & Executive Chairman
Dr. Neil P. Desai Ph.D.
Founder, Secretary & Executive Chairman
Dr. Neil P. Desai Ph.D.
Headquarters
Pacific Palisades, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aadi Bioscience Inc (AADI) stood at $ 70 Mln as on 31-Dec-24
The share price of Aadi Bioscience Inc (AADI) is $1.57 (NASDAQ) as of 17-Apr-2025 09:30 EDT. Aadi Bioscience Inc (AADI) has given a return of -54.36% in the last 3 years.
Aadi Bioscience Inc (AADI) has a market capitalisation of $ 95 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aadi Bioscience Inc (AADI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aadi Bioscience Inc (AADI) and enter the required number of quantities and click on buy to purchase the shares of Aadi Bioscience Inc (AADI).
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
The CEO & director of Dr. Neil P. Desai Ph.D.. is Aadi Bioscience Inc (AADI), and CFO & Sr. VP is Dr. Neil P. Desai Ph.D..
There is no promoter pledging in Aadi Bioscience Inc (AADI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Aadi Bioscience Inc. (AADI) | Ratios |
|---|---|
|
Return on equity(%)
|
-80.79
|
|
Operating margin(%)
|
-249.47
|
|
Net Margin(%)
|
-245.13
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aadi Bioscience Inc (AADI) was $0 Mln.
$-0.45
(
